Patients with hidradenitis suppurativa (HS), atopic dermatitis (AD), and plaque psoriasis often experience sleeping problems. In HS, pain and itch increases the frequency of insomnia, and the pain was associated to poor sleeping quality .
Dermatoses like HS, AD, and psoriasis entail varying intensities of itch and pain that can have a negative influence on the quality of life of the affected patients. Dr Karolina Kaaz (Wroclaw Medical University, Poland) and her colleagues evaluated the influence of itch and pain on the sleep of HS patients and compared this with AD and psoriasis patients. Data on 108 patients with HS, 100 with AD, and 100 with psoriasis were included. The HS patients had a mean age 36.3, 47% was female, and their mean Hidradenitis Severity Score was 34.8. In the AD group, 42% was female, mean age 39.2, and patients had a mean Scoring of Atopic Dermatitis (SCORAD) of 33.6, while the psoriasis patients were aged 44.1 years, 39% was female, and they had a mean Psoriasis Area and Severity Index score (PASI) of 13.5.
Itch and pain were assessed using a visual analogue scale (VAS). Insomnia and sleep quality were evaluated by the Athens Insomnia Scale (AIS) and the Pittsburgh Sleep Quality Index. The 3 groups showed mean values in Dermatology Life Quality Index (DLQI) of 13.0 (HS), 16.4 (AD), and 12.8 (psoriasis). Severe itch was only present in 14% of HS, but 60% of AD and 46% of psoriasis patients. Looking at pain rates in the HS group, the investigators found 21% severe, 17% moderate, and 42% mild pain. 66% of the AD and 83% of the psoriasis subjects did not report any pain and only 13% of AD and 11% of psoriasis patients suffered from severe pain.
In HS patients, a significant correlation between grade of itch/pain and AIS scores was found (P=0.03). Mean AIS scores for HS were lower than those in AD (P<0.0001) and psoriasis (P=0.02). With mean total scores of 6.5, 8.3, and 8.1, 70% of HS and 80% of AD/PP patients were over the cut-off value of ≥ 5, which stands for poor sleeping quality. In HS, the magnitude of itch and pain correlated to the established AIS values.
The authors concluded that the impact of itch was important for patients of all 3 chronic dermatoses. Especially for HS, they emphasised that itch and pain did not only affect insomnia incidence, but pain also influenced sleep quality.
- Kaaz K, et al. P1846, EADV 2019, 9-13 Oct, Madrid, Spain.
« Systemic photoprotection: a valuable addition to topical sun protection Next Article
IL-17 blocker: effective and safe in patients with comorbidities »
Table of Contents: EADV 2019
Letter from the Editor
IL-17A blocker effective in paediatric psoriasis patients
Rituximab beats mycophenolate mofetil in pemphigus vulgaris
Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata
Acne highly influenced by climate, pollutants, and unhealthy diet
JAK inhibition plus TCS lead to high clearance rates in AD
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Topical ruxolitinib effective in vitiligo
Small molecules: interesting novel treatment options in AD
IL-1⍺ blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
Spotlight on Psoriasis
IL-17 blocker: effective and safe in patients with comorbidities
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
No hint of teratogenicity through ixekizumab
New Insights in Photoprotection
Systemic photoprotection: a valuable addition to topical sun protection
The underestimated effect of visible light
Comorbidities more common in chronic urticaria, psoriasis, and AD
D-Dimer as future biomarker in CSU management?
Ligelizumab for CSU: symptom control and high response rates in re-treatment
Rosacea – From New Spectrum to New Therapy
New guidance on rosacea therapy according to phenotype
Best of the Posters
Above-the-neck melanoma more prone to metastases
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
Certolizumab pegol efficacious for head and neck psoriasis
Psoriasis and PsA in transgender adults on hormone therapy